The concomitant use of VYVANSE and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of VYVANSE compared to the use of the drug alone and increase the risk of serotonin syndrome. Medicines are sometimes prescribed for purposes other than those listed rein a Medication Guide. Do not https://franciscob035ive5.yomoblog.com/profile